"The U.S. Food and Drug Administration today expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
Fusilev Patient Information including How Should I Take
In this Article
- What is levoleucovorin (Fusilev)?
- What are the possible side effects of levoleucovorin (Fusilev)?
- What is the most important information I should know about levoleucovorin (Fusilev)?
- What should I discuss with my healthcare provider before I receive levoleucovorin (Fusilev)?
- How is levoleucovorin given (Fusilev)?
- What happens if I miss a dose (Fusilev)?
- What happens if I overdose (Fusilev)?
- What should I avoid while receiving levoleucovorin (Fusilev)?
- What other drugs will affect levoleucovorin (Fusilev)?
- Where can I get more information?
What should I discuss with my healthcare provider before I receive levoleucovorin (Fusilev)?
You should not receive this medication if you are allergic to levoleucovorin or to folic acid or folinic acid.
If possible, before you receive levoleucovorin, tell your doctor or caregivers if you have:
- kidney disease;
- liver disease; or
- if you are dehydrated.
FDA pregnancy category C. It is not known whether levoleucovorin will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medication.
It is not known whether levoleucovorin passes into breast milk or if it could harm a nursing baby. You should not breast-feed while you are using levoleucovorin.
In an emergency situation, it may not be possible before you are treated with levoleucovorin to tell your caregivers if you are pregnant or breast feeding. Make sure any doctor caring for your pregnancy or your baby knows you have received this medication.
How is levoleucovorin given (Fusilev)?
Levoleucovorin is injected into a vein through an IV. You will receive this injection in a clinic or hospital setting. Levoleucovorin must be given slowly, and the IV infusion can take up to 4 hours to complete.
When treating or preventing methotrexate toxicity, levoleucovorin is usually given every 6 hours for 10 doses. You will most likely receive your first dose 24 hours after the start of your methotrexate infusion, or as soon as possible within the first 24 hours after accidental overdose.
After treatment with levoleucovorin, you will be watched to make sure the medication has been effective and you no longer have any effects of methotrexate.
When treating colorectal cancer levoleucovorin is usually given daily as a 5-day treatment, repeated every 4 to 5 weeks.
To be sure this medication is helping your condition and is not causing harmful effects, your blood will need to be tested often. This will help your doctor determine if your dose needs to be adjusted and how long to treat you with levoleucovorin. Visit your doctor regularly.
Additional Fusilev Information
- Fusilev Drug Interactions Center: levoleucovorin calcium iv
- Fusilev Side Effects Center
- Fusilev FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.